SORL1 and neoplasm: Furthermore, our CAM assay data show similar anti‐tumor effects between a full and a reduced dose of SorLA ab and trastuzumab combination treatment suggesting that even lower doses of SorLA ab treatment with reduced risk of adverse effects may reach therapeutic efficacy in vivo.